{"created":"2023-06-19T11:23:41.081524+00:00","id":4257,"links":{},"metadata":{"_buckets":{"deposit":"2ac8877c-ba37-4839-806e-4671d42c9ee9"},"_deposit":{"created_by":3,"id":"4257","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"4257"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:00004257","sets":["7","7:24"]},"author_link":["13135","13136","13137","13138","13139","13140","13141","13142","13143","13144"],"control_number":"4257","item_1716186501932":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"22053850","subitem_relation_type_select":"PMID"}}]},"item_5_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-11-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageStart":"191","bibliographicVolumeNumber":"5","bibliographic_titles":[{"bibliographic_title":"Journal of translational medicine"}]}]},"item_5_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background T-cell based immunotherapy for lung cancer (LC) could be a promising and novel therapeutic approach. Six-transmembrane epithelial antigen of the prostate (STEAP) and the polycomb group protein enhancer of zeste homolog 2 (EZH2) are highly expressed in LC and since the expression of molecules in normal tissue is significantly lower as compared to tumor cells, these proteins are considered as potential tumor-associated antigens (TAAs) for developing T-cell based immunotherapy. \\nMethods We assessed the capacity of predicted CD4 T-cell epitopes from STEAP and EZH2 to induce anti-tumor immune responses to LC cell lines. \\nResults Out of several predicted epitopes, two synthetic peptides, STEAP281-296 and EZH295-109, were effective in inducing CD4 T-cell responses that were restricted by HLA-DR1, DR15, or DR53 molecules, indicating that the peptides function as promiscuous T-cell epitopes. Moreover, STEAP281-296 and EZH295-109-reactive T-cells could directly recognize STEAP or EZH2 expressing LC cells in an HLA-DR restricted manner. In addition, some STEAP-reactive T-cells responded to STEAP+ tumor cell lysates presented by autologous dendric cells. Most significantly, both of these peptides were capable of stimulating in vitro T-cell responses in patients with LC. \\nConclusions Peptides STEAP281-296 and EZH295-109 function as strong CD4 T-cell epitopes that can elicit effective anti-tumor T-cell responses against STEAP or EZH2 expressing LC. These observations may facilitate the translation of T-cell based immunotherapy into the clinic for the treatment of LC.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_description_36":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_description":"Publisher","subitem_description_type":"Other"}]},"item_5_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"text","subitem_description_type":"Other"}]},"item_5_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_5_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/1479-5876-9-191","subitem_relation_type_select":"DOI"}}]},"item_5_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1479-5876","subitem_source_identifier_type":"PISSN"}]},"item_5_text_44":{"attribute_name":"ID(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"22053850"}]},"item_5_text_54":{"attribute_name":"閲覧数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"717"}]},"item_5_text_55":{"attribute_name":"ダウンロード数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"321"}]},"item_5_version_type_38":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"林, 諭史","creatorNameLang":"ja"},{"creatorName":"ハヤシ, サトシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"13135","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kumai, T","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13136","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsuda, Y","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13137","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Aoki, N","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13138","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sato, K","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13139","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kimura, S","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13140","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kitada, M","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13141","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tateno, M","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13142","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Celis, E","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13143","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kobayashi, H","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"13144","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-06"}],"displaytype":"detail","filename":"4995.pdf","filesize":[{"value":"243.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"4995.pdf","url":"https://asahikawa-med.repo.nii.ac.jp/record/4257/files/4995.pdf"},"version_id":"d28ce800-5960-4d94-8460-543791fcd055"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer","subitem_title_language":"en"}]},"item_type_id":"5","owner":"3","path":["6","7","24"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-01-25"},"publish_date":"2013-01-25","publish_status":"0","recid":"4257","relation_version_is_last":true,"title":["Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2024-08-09T07:40:58.152261+00:00"}